Author

F. Nunez

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:mouse· 3 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

J. C. Gauss· 2 shared M. Edwards· 2 shared M. G. Castro· 2 shared M. Garcia-Fabiani· 2 shared P. Kadiyala· 2 shared P. Lowenstein· 2 shared S. Carney· 2 shared A. Schwendeman· 1 shared

Activity by Year

2019-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 34 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

J. C. Gauss

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

G-CSF SECRETED BY EPIGENETICALLY REPROGRAMMED MUTANT IDH1 GLIOMA STEM CELLS REVERSES THE MYELOID CELLS'-MEDIATED IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT

M. S. Alghamri, R. Avvari, R. Thalla, N. Kamran, L. Zhang, M. Ventosa, A. Taher, S. Faisal, F. Nunez, M. Garcia-Fabiani, S. Haase, S. Carney, D. Orringer, S. Hervey-Jumper, J. Heth, , M. G. Castro

The paper shows that mIDH1 glioma stem cells secrete G-CSF, which reprograms myeloid cells to become non-immunosuppressive, altering the tumor microenvironment.

bioRxiv · Jul 22, 2020 · PreprintCancer Biology

Inhibition of 2-Hydroxyglutrate Elicits Metabolic-reprograming and Mutant IDH1 Glioma Immunity

P. Kadiyala, S. V. Carney, J. C. Gauss, M. Garcia-Fabiani, F. Nunez, F. M. Nunez, M. Alghamri, Y. Liu, M. Yu, D. Li, M. Edwards, J. J. Moon, A. Schwendeman, P. R. Lowenstein, M. Castro

This study shows that inhibiting 2-hydroxyglutarate in mIDH1 gliomas with ATRX/TP53 inactivation improves survival and induces anti-tumor immunity through immunological memory and reduced T-cell exhaustion.

bioRxiv · May 11, 2020 · PreprintImmunology

Therapeutic efficacy of an immune stimulatory gene therapy strategy in a mouse model of high grade brainstem glioma

F. M. Mendez, P. Kadiyala, F. J. Nunez, S. Carney, F. Nunez, J. C. Gauss, R. Ravindran, S. Pawar, M. Edwards, P. Lowenstein, M. G. Castro

This paper tests an immune-stimulatory gene therapy in a mouse model of DIPG, showing increased survival and anti-tumor immunity through adenoviral delivery of TK and Flt3L.

bioRxiv · Nov 18, 2019 · PreprintCancer Biology